1 – 10 of 40
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Change in Cell Death Markers During (177)Lu-mAb Radioimmunotherapy-Induced Rejection of Syngeneic Rat Colon Carcinoma.
(
- Contribution to journal › Article
- 2013
-
Mark
The Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies Changes in Relation to Tumor Histology over Time in a Syngeneic Rat Colon Carcinoma Model.
(
- Contribution to journal › Article
- 2011
-
Mark
Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
(
- Contribution to journal › Article
- 2010
-
Mark
90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
(
- Contribution to journal › Article
-
Mark
High-Dose Radioimmunotherapy Combined With Extracorporeal Depletion in a Syngeneic Rat Tumor Model
(
- Contribution to journal › Article
-
Mark
Lu-177-[DOTA0,Tyr3] Octreotate Therapy in Patients With Disseminated Neuroendocrine Tumors: Analysis of Dosimetry With Impact on Future Therapeutic Strategy
(
- Contribution to journal › Article
- 2009
-
Mark
Peptide Receptor Radionuclide Therapy (PRRT) Using 177Lu-DOTATATE: Early Clinical and Dosimetric Results
2009) 6th Annual Conference of the European-Neuroendocrine-Tumor-Society In Neuroendocrinology 90(1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
(
- Contribution to journal › Article
- 2008
-
Mark
High dose radioimmunotherapy combined with extracorporeal depletion in syngeneic rat tumor model. Evaluation of toxicity, therapeutic effect, and tumor model
2008) Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates In Cancer Biotherapy and Radiopharmaceuticals 23(4). p.517-517(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy
(
- Contribution to journal › Article